Inclusion Criteria:  Histologically proven initial diagnosis of adenocarcinoma of the prostate; Clinical stage T1-4 N0 M0; Prostatic assessment by multiparametric (mp) MRI; Pelvic lymph node was assessed by PSMA PET/CT and mpMRI; No distant metastasis was proven by PSMA PET/CT; Patients may received neoadjuvant hormonal therapy; 45≤ Age ≤85; Adequate performance status (ECOG 0-1); No previous pelvic radiation therapy (RT); No previous prostatectomy; No previous invasive cancer (within 5 years before the prostate cancer diagnosis); Ability to understand character and individual consequences of the clinical trial; Written informed consent;  Exclusion Criteria:  No pathologically confirmed adenocarcinoma of the prostate; Distant metastasis (M1); Previous pelvic radiotherapy; Previous prostatectomy;